Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus ENSTILAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus ENSTILAR.
CAPEX vs ENSTILAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid and Vitamin D Analog